Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.
Hakenberg, Oliver W.; Perez-Gracia, Jose Luis; Castellano, Danielet al.
2019 • In European journal of cancer (Oxford, England : 1990), 107, p. 186-195
[en] INTRODUCTION: Platelet-derived growth factor receptor-alpha (PDGFRalpha) is expressed in primary prostate adenocarcinoma and in associated skeletal metastases. Olaratumab is a fully human monoclonal antibody that binds PDGFRalpha and blocks downstream signalling. This phase II study assessed the efficacy and safety of olaratumab in combination with mitoxantrone and prednisone (M/P) versus M/P alone in patients with metastatic castration-resistant prostate cancer (mCRPC) who progressed after docetaxel. METHODS: Patients were randomised to receive 21-d cycles of olaratumab (15 mg/kg, Days 1 and 8) plus mitoxantrone (12 mg/m(2), Day 1) and prednisone (5 mg, twice daily) or M/P alone. Progression-free survival (PFS) was the primary end-point. Secondary end-points included overall survival (OS), safety, and circulating tumour cell (CTC) counts. RESULTS: A total of 123 patients were randomised, 63 to olaratumab + M/P and 60 to M/P. Median PFS was 2.3 months for olaratumab + M/P and 2.4 months for M/P (hazard ratio [HR] = 1.29; 95% confidence interval [CI] = 0.87-1.90). Median OS was 14.2 months for olaratumab + M/P and 12.8 months for M/P (HR = 1.08; 95% CI = 0.72-1.61). Both treatment arms had similar toxicity profiles; neutropenia (24% versus 15%), anaemia (13% versus 14%) and fatigue (11% versus 9%) (olaratumab + M/P versus M/P, respectively) were the most common grade >/=3 events. High CTC count was associated with poorer OS in both arms. Patients with very high cell counts (>37 cells/7.5 ml) exhibited improved OS with olaratumab + M/P (interaction P = 0.043). CONCLUSIONS: Olaratumab + M/P had an acceptable safety profile but did not improve the efficacy of M/P chemotherapy. Further study with selected patient populations and earlier in the disease course might be considered.
Disciplines :
Oncology
Author, co-author :
Hakenberg, Oliver W.
Perez-Gracia, Jose Luis
Castellano, Daniel
Demkow, Tomasz
Ali, Tarek
Caffo, Orazio
Heidenreich, Axel
Schultze-Seemann, Wolfgang
Sautois, Brieuc ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques
Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.
Publication date :
2019
Journal title :
European journal of cancer (Oxford, England : 1990)
Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., Mathers, C., et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11. Internet, 2013, International Agency for Research on Cancer, Lyon, France Available from: http://globocan.iarc.fr [accessed 26 April 2017].
Loblaw, D.A., Walker-Dilks, C., Winquist, E., Hotte, S.J., Genitourinary Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care. Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review. Clin Oncol 25 (2013), 406–430.
Basch, E., Loblaw, D.A., Oliver, T.K., Carducci, M., Chen, R.C., Frame, J.N., et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol 32 (2014), 3436–3448.
Crawford, E.D., Higano, C.S., Shore, N.D., Hussain, M., Petrylak, D.P., Treating patients with metastatic castration resistant prostate cancer: a comprehensive review of available therapies. J Urol 194 (2015), 1537–1547.
Tannock, I.F., Osoba, D., Stockler, M.R., Ernst, D.S., Neville, A.J., Moore, M.J., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14 (1996), 1756–1764.
Kantoff, P.W., Halabi, S., Conaway, M., Picus, J., Kirshner, J., Hars, V., et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 17 (1999), 2506–2513.
Rosenberg, H.E., Weinberg, V.K., Kelly, W.K., Michaelson, D., Hussain, M.H., Wilding, G., et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients. Cancer 110 (2007), 556–563.
Heldin, C.H., Targeting the PDGF signaling pathway in tumor treatment. Cell Commun Signal, 11, 2013, 97.
Paulsson, J., Ehnman, M., Ostman, A., PDGF receptors in tumour biology: prognostic and predictive potential. Future Oncol 10 (2014), 1695–1708.
Gialeli, C., Nikitovic, D., Kletsas, D., Theocharis, A.D., Tzanakakis, G.N., Karamanos, N.K., PDGF/PDGFR signaling and targeting in cancer growth and progression: focus on tumor microenvironment and cancer-associated fibroblasts. Curr Pharmaceut Des 20 (2014), 2843–2848.
Shah, G.D., Loizos, N., Youssoufian, H., Schwartz, J.D., Rowinsky, E.K., Rationale for the development of IMC-3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet-derived growth factor receptor alpha. Cancer 116 (2010), 1018–1026.
Loizos, N., Xu, Y., Huber, J., Liu, M., Lu, D., Finnerty, B., et al. Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target. Mol Canc Therapeut 4 (2005), 369–379.
Tap, W.D., Jones, R.L., Van Tine, B.A., Chmielowski, B., Elias, A.D., Adkins, D., et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet 388 (2016), 488–497.
Russell, M.R., Liu, Q., Fatatis, A., Targeting the α receptor for platelet-derived growth factor as a primary or combination therapy in a preclinical model of prostate cancer skeletal metastasis. Clin Canc Res 16 (2010), 5002–5010.
D'Oronzo, S., Brown, J., Coleman, R., The role of biomarkers in the management of bone-homing malignancies. J Bone Oncol 9 (2017), 1–9.
Chiorean, E.G., Sweeney, C., Amato, R.K., Katz, T., Fox, F., Youssoufian, H., et al. Phase 1 study of IMC-3G3, an IgG1 monoclonal antibody targeting PDGFR-alpha in patients with advanced solid malignancies. EORTC-NCI-AACR Annual meeting 2008. October 21–24, 2018 Geneva, Switzerland.
Eisenhauer, E.A., Therasse, P., Bogaerts, J., Schwartz, L.H., Sargent, D., Ford, R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2009), 228–247.
U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events v4·0 (CTCAE), 5/2009 update. http://evs.nci.nih.gov/ftp1/CTCAE/Archive/CTCAE_4.02_2009-09-15_QuickReference_8.5x11.pdf. [accessed 26 April 2017].
de Bono, J.S., Scher, H.I., Montgomery, R.B., Parker, C., Miller, M.C., Tissing, H., et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Canc Res 14 (2008), 6302–6309.
Kaplan, E.L., Meier, P., Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958), 457–481.
Rosenberg, A., Mathew, P., Imatinib and prostate cancer: lessons learned from targeting the platelet-derived growth factor receptor. Expet Opin Invest Drugs 22 (2013), 787–794.
Wyatt, A.W., Gleave, M.E., Targeting the adaptive molecular landscape of castration-resistant prostate cancer. EMBO Mol Med 7 (2015), 878–894.
Friedman, R., Drug resistance in cancer: molecular evolution and compensatory proliferation. Oncotarget 7 (2016), 11746–11755.
Michaelson, M.D., Oudard, S., Ou, Y.C., Sengeløv, L., Saad, F., Houede, N., et al. Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. J Clin Oncol 32 (2013), 76–82.
Smith, M., De Bono, J., Sternberg, C., Le Moulec, S., Oudard, S., De Giorgi, U., et al. Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1. J Clin Oncol 34 (2016), 3005–3013.
Tannock, I.F., de Wit, R., Berry, W.R., Horti, J., Pluzanska, A., Chi, K.N., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004), 1502–1512.
Scher, H.I., Heller, G., Molina, A., Attard, G., Danila, D.C., Jia, X., et al. Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. J Clin Oncol 33 (2015), 1348–1355.
Bastos, D.A., Antonarakis, E.S., CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer. Expert Rev Mol Diagn 18 (2018), 155–163.
